Publications by authors named "I E Kanonidis"
Background: National heart failure guidelines recommend quadruple therapy with renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 inhibitors for patients with heart failure with reduced ejection fraction (HFrEF), most of whom also receive loop diuretics. However, the guidelines are less clear about the safe approaches to discontinuing older drugs whose decreasing or residual benefit is less well understood. The objective of this study was to examine whether digoxin can be safely discontinued in patients with HFrEF receiving beta-blockers.
View Article and Find Full Text PDFArticle Synopsis
- Renin-angiotensin system inhibitors can enhance outcomes for patients with heart failure and reduced ejection fraction (HFrEF), but their effectiveness in those with advanced kidney disease was less understood.
- In a study involving 1,582 patients with HFrEF and severe kidney issues, researchers analyzed the effects of starting ACE inhibitors or ARBs on patient outcomes.
- The results indicated that patients who started these medications experienced better outcomes regarding heart failure readmissions and overall mortality, suggesting that these drugs may be beneficial for this specific patient group.
Background: In patients with heart failure with reduced ejection fraction (HFrEF) and hypertension, systolic blood pressure is recommended to be maintained below 130 mmHg, although this has not been shown to be associated with improved outcomes. We examined the association between anti-hypertensive drug initiation and outcomes in patients with HFrEF.
Methods: In the Medicare-linked OPTIMIZE-HF, 7966 patients with HFrEF (ejection fraction ≤40%) without renal failure were not receiving anti-hypertensive drugs before hospitalization, of whom 692 received discharge prescriptions for those drugs (thiazides and calcium channel blockers).
Background: RBP4 is an adipokine with an established role in atherosclerosis, while adiponectin has unique anti-inflammatory properties. We investigated the association of RBP4 and adiponectin with the presence of symptomatic peripheral artery disease (PAD) and their possible prognostic role in major adverse cardiovascular events (MACE).
Methods: We enrolled 168 consecutive patients with symptomatic, established PAD, requiring revascularization by endovascular means of any or both of their lower limbs.